Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brentuximab vedotin - Seagen/Takeda Oncology

Next Previous
Drug Profile

Brentuximab vedotin - Seagen/Takeda Oncology

Alternative Names: Adcetris; Anti-CD30-MMAE; Anti-CD30-monoclonal-antibody-cAC10-auristatin-E-conjugate; Auristatin-E-anti-CD30-monoclonal-antibody-cAC10-conjugate; Brentuximab; cAC10-vcMMAE; MMAE-anti-CD30; SGN-35

Latest Information Update: 22 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seattle Genetics; Stanford University
  • Developer Bristol-Myers Squibb; Celgene Corporation; Dana-Farber Cancer Institute; Fondazione Italiana Linfomi; Fox Chase Cancer Center; Immune Tolerance Network; Lymphoma Academic Research Organisation; Massachusetts General Hospital; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; Seagen; Seattle Genetics; Stanford University; Takeda; Takeda Oncology; UNC Lineberger Comprehensive Cancer Center; Washington University School of Medicine
  • Class Antineoplastics; Antiretrovirals; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies; Oligopeptides; Skin disorder therapies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease; Lymphoproliferative disorders; Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; Primary cutaneous anaplastic large cell lymphoma; Mycosis fungoides
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic large cell lymphoma; Hodgkin's disease; Mycosis fungoides; Peripheral T-cell lymphoma; Primary cutaneous anaplastic large cell lymphoma; T-cell lymphoma
  • Registered Diffuse large B cell lymphoma
  • Phase II Adult T-cell leukaemia-lymphoma; Diffuse scleroderma; Germ cell cancer; Malignant-mesothelioma; Mastocytosis; Non-Hodgkin's lymphoma; Sezary syndrome; Solid tumours
  • Phase I HIV-1 infections
  • No development reported Graft-versus-host disease
  • Discontinued Leukaemia; Multiple myeloma; Systemic lupus erythematosus

Most Recent Events

  • 02 Apr 2025 NICE Consortium recommend brentuximab vedotin in combination with doxorubicin, dacarbazine and vinblastine for routine use in Non Hodgkin's lymphoma
  • 12 Feb 2025 Registered for Diffuse large B cell lymphoma (Second-line therapy or greater, Combination therapy) in USA (IV)
  • 07 Dec 2024 Efficacy and adverse events data from phase III ECHELON-3 trial in Diffuse large B-cell lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top